These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 37422670)

  • 1. Unresolved questions in selection of therapies for treatment-naïve chronic lymphocytic leukemia.
    Bennett R; Anderson MA; Seymour JF
    J Hematol Oncol; 2023 Jul; 16(1):72. PubMed ID: 37422670
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Frontline treatment in CLL: the case for time-limited treatment.
    Lévy V; Delmer A; Cymbalista F
    Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):59-67. PubMed ID: 34889444
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-world comparison of health care costs of venetoclax-obinutuzumab vs Bruton's tyrosine kinase inhibitor use among US Medicare beneficiaries with chronic lymphocytic leukemia in the frontline setting.
    Huntington SF; Manzoor BS; Jawaid D; Puckett JT; Emechebe N; Ravelo A; Kamal-Bahl S; Doshi JA
    J Manag Care Spec Pharm; 2024 Oct; 30(10):1106-1116. PubMed ID: 39046941
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BCL-2 Inhibition as Treatment for Chronic Lymphocytic Leukemia.
    Perini GF; Feres CCP; Teixeira LLC; Hamerschlak N
    Curr Treat Options Oncol; 2021 Jun; 22(8):66. PubMed ID: 34110507
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Update on the management of relapsed/refractory chronic lymphocytic leukemia.
    Bennett R; Seymour JF
    Blood Cancer J; 2024 Feb; 14(1):33. PubMed ID: 38378673
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted multigene deep sequencing of Bruton tyrosine kinase inhibitor-resistant chronic lymphocytic leukemia with disease progression and Richter transformation.
    Kanagal-Shamanna R; Jain P; Patel KP; Routbort M; Bueso-Ramos C; Alhalouli T; Khoury JD; Luthra R; Ferrajoli A; Keating M; Jain N; Burger J; Estrov Z; Wierda W; Kantarjian HM; Medeiros LJ
    Cancer; 2019 Feb; 125(4):559-574. PubMed ID: 30508305
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Approaches for relapsed CLL after chemotherapy-free frontline regimens.
    Roeker LE; Mato AR
    Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):10-17. PubMed ID: 33275712
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Review of Resistance Mechanisms to Bruton's Kinase Inhibitors in Chronic Lymphocytic Leukemia.
    Wiśniewski K; Puła B
    Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791284
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is there a role for anti-CD20 antibodies in CLL?
    Shah HR; Stephens DM
    Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):68-75. PubMed ID: 34889417
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of Bruton's kinase inhibitors (BTKi) in accelerated Chronic Lymphocytic Leukemia (a-CLL): a case of successful response to acalabrutinib.
    Catania G; Tavarozzi R; Pini GM; Borra T; Gandolfo C; Zacchi G; Pietrasanta D; Monaco F; Zanni M; Lettieri M; Rivela P; Zallio F; Ladetto M
    J Basic Clin Physiol Pharmacol; 2023 May; 34(3):401-404. PubMed ID: 37040263
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world comparative effectiveness of venetoclax-obinutuzumab versus Bruton tyrosine kinase inhibitors for frontline chronic lymphocytic leukaemia.
    Ghosh N; Manzoor BS; Fakhri B; Emechebe N; Alhasani H; Skarbnik A; Jawaid D; Shadman M
    Br J Haematol; 2024 Oct; 205(4):1395-1403. PubMed ID: 39049159
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular-Biology-Driven Frontline Treatment for Chronic Lymphocytic Leukemia: A Network Meta-Analysis of Randomized Clinical Trials.
    Rizzuto A; Pirrera A; Gigliotta E; Mancuso S; Vullo C; Camarda GM; Rotolo C; Roppolo A; Spoto C; Gentile M; Botta C; Siragusa S
    Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373078
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Approved and emerging Bruton's tyrosine kinase inhibitors for the treatment of chronic lymphocytic leukemia.
    Hatashima A; Karami M; Shadman M
    Expert Opin Pharmacother; 2022 Sep; 23(13):1545-1557. PubMed ID: 35973973
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and Safety of Bruton Tyrosine Kinase Inhibitor Plus Anti-CD20 Antibody Therapy Compared With Chemoimmunotherapy as Front-line Treatment for Chronic Lymphocytic Leukemia: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
    Nguyen TT; Thanh Nhu N; Tran VK; Van Cau N; Lin CF
    J Immunother; 2023 Oct; 46(8):299-309. PubMed ID: 37216406
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of new-generation Bruton tyrosine kinase inhibitors in chronic lymphocytic leukemia/small lymphocytic lymphoma: a systematic review and meta-analysis.
    Yin S; Zheng X; Zhang W; Zhao H; Zhang R; Li W; Chen F
    Ann Hematol; 2024 Jul; 103(7):2231-2244. PubMed ID: 37843620
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL).
    Odetola O; Ma S
    Curr Hematol Malig Rep; 2023 Oct; 18(5):130-143. PubMed ID: 37278884
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BTK inhibitors: moving the needle on the treatment of chronic lymphocytic leukemia.
    Hatashima A; Shadman M
    Expert Rev Hematol; 2024 Oct; 17(10):687-703. PubMed ID: 39163531
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Current diagnosis and treatment of chronic lymphocytic leukaemia].
    Cramer P; von Tresckow J; Eichhorst B; Hallek M
    Dtsch Med Wochenschr; 2020 Aug; 145(16):1139-1144. PubMed ID: 32791549
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of Chronic Lymphocytic Leukemia After Discontinuation of Bruton's Tyrosine Kinase Inhibitors.
    Thompson MC; Mato AR
    Hematol Oncol Clin North Am; 2021 Aug; 35(4):793-806. PubMed ID: 34174986
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-World Health Care Resource Use and Costs Among Patients With Chronic Lymphocytic Leukemia Treated With Venetoclax-Based and Bruton Tyrosine Kinase Inhibitor-Based Regimens in the Second-Line Setting.
    Fakhri B; Emechebe N; Manzoor BS; Jawaid D; Alhasani H; Edwards M; Tuncer HH
    JCO Oncol Pract; 2024 Aug; 20(8):1132-1139. PubMed ID: 38626366
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.